In Person

Nasdaq IPO Day

November 9, 2023
Gide Loyrette Nouel
Event details
November 9, 2023
2:00 – 7:00 pm Central European Time
Gide Loyrette Nouel
15 rue de Laborde
Paris, France

Event summary

Gide Loyrette Nouel and Cooley, top in the market in helping French biotechs list on the Nasdaq stock exchange, hosted this exclusive half-day event tailored specifically for executives of French biotech companies considering a listing on Nasdaq. This event at Gide’s office in central Paris is designed to provide valuable insights and skilled guidance on navigating the complex journey of going public on the most active exchange in the US. In addition to French and US securities law practitioners from Gide and Cooley, sessions featured market practitioners from Jefferies, Ernst & Young, and Namsen Capital.





Opening remarks and introductions

Arnaud Duhamel – Partner at Gide
Marc Recht – Partner at Cooley


Market Update

In this session, you’ll learn the latest on the US capital markets, with a focus on recent French biotech market activity on Nasdaq.

Gil Bar-Nahum – Managing director at Jefferies


IPO Process Overview

This session provides a high-level overview of the timeline and structure of a Nasdaq listing, plus information about the transition to a dual listing on Euronext Paris and Nasdaq.

Katie Kazem – Partner at Cooley
Guilhem Richard – Partner at Gide
Cedric Garcia – Partner at Ernst & Young




You Listed on Nasdaq … Now What?

In this session, we highlight the opportunities and challenges experienced by French Nasdaq-listed companies, from capital raising – including follow-on offerings, at-the-market offerings and debt offerings – to managing US and non-US investor expectations, corporate governance matters and, of course, compliance with accounting standards.

David Boles (co-moderator) – Partner at Cooley
Eric Blanchard (co-moderator) – Partner at Cooley
Arnaud Duhamel – Partner at Gide
Gil Bar-Nahum – Managing director at Jefferies
Eric Soyer – Chief financial officer at Phaxiam
Stefanie Magner – Chief compliance officer and EVP of international legal affairs at GENFIT




War Stories From the Nasdaq Listing Frontline

In a conversation with key players, including members of the C-suite, who have recently completed a French biotech Nasdaq listing, this session delves into lessons learned and goes behind the scenes – beyond the transactional aspects of an initial public offering.

Courtney Thorne (moderator) – Partner at Cooley
Gil Bar-Nahum – Managing director at Jefferies
Cedric Moreau – Partner, crossover strategy, at Sofinnova Partners
Jean-Baptiste Célard – Founder of Namsen Capital
Jean Volatier – Chief financial officer at Inventiva
Didier Blondel – Executive vice president and chief financial officer at Abivax
David Lawrence – Former chief financial officer at Valneva


Closing remarks

Arnaud Duhamel – Partner at Gide
Marc Recht – Partner at Cooley


Cocktail hour



About Gide Loyrette Nouel

Gide has a long tradition of excellence in advising growth companies and investors in the healthtech sector. From venture capital transactions and seed capital funding to IPOs on Euronext Paris and the Nasdaq market, our teams provide outstanding advice in a full range of services including M&A, finance, intellectual property, regulatory and antitrust in the healthcare and life sciences industries.

About Cooley

For more than 40 years, Cooley’s top-ranked team has represented innovators and investors across cutting-edge fields in the healthcare and life sciences industries. Cooley leverages its global, full-service platform to advise on financing, corporate partnering and licensing, M&A and public offerings, as well as litigation, regulatory and intellectual property needs. No other legal team boasts Cooley’s level of experience guiding healthcare and life sciences companies throughout every stage of growth.

For more information, please email Kelsey O’Connell.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.